PKD1L1

Across TCGA pan-cancer cohorts, PKD1L1 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PKD1L1 data layer compared with 11 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher PKD1L1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PKD1L1 expression acts as an unfavorable survival marker, although some lineages such as KIRC and READ show a favorable association.

MESO, CESC, and KIRC are the cancer types where PKD1L1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.242	0.556	<.001	97	view →
CESC	DFS	Quartile	All	0.645	0.881	<.001	94	view →
KIRC	OS	Median	All	0.698	0.562	<.001	88	view →
READ	OS	Median	II,III,IV	0.987	0.839	<.001	66	view →
LGG	DFS	Median	All	0.618	0.855	<.001	54	view →
KIRP	DFS	Tertile	All	0.611	0.897	.005	43	view →
PAAD	DFS	Quartile	II,III,IV	0.603	0.303	<.001	31	view →
ACC	OS	Median	III,IV	0.318	0.878	.001	29	view →
STAD	DFS	Median	All	0.478	0.621	.001	24	view →
OV	DFS	Median	III,IV	0.490	0.571	.025	20	view →
LUAD	DFS	Tertile	IV	0.471	0.876	.026	18	view →
SCLC	DFS	Median	IV	0.137	0.559	.008	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PKD1L1–MESO (OS)

Open the MESO breakdown →